Pacira BioSciences (PCRX) Change in Receivables (2010 - 2026)

Pacira BioSciences' Change in Receivables history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 118.31% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $20.9 million (up 571.86% YoY), while the FY2025 annual figure was $10.7 million, up 38.64% from the prior year.
• Change in Receivables was $1.6 million for Q1 2026 at Pacira BioSciences, down from $8.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $12.7 million in Q4 2024 to a low of -$8.6 million in Q1 2025.
• Historically, Change in Receivables has averaged $1.7 million across 5 years, with a median of $1.6 million in 2026.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables tumbled 812.34% in 2022, then soared 688.68% in 2023.
• A 5-year view of Change in Receivables shows it stood at $4.9 million in 2022, then jumped by 74.56% to $8.6 million in 2023, then soared by 47.12% to $12.7 million in 2024, then sank by 30.45% to $8.8 million in 2025, then slumped by 82.19% to $1.6 million in 2026.
• The last three Change in Receivables figures came in at $1.6 million (Q1 2026), $8.8 million (Q4 2025), and $897000.0 (Q3 2025), per Business Quant data.